Atrandi Biosciences is breaking new ground in high-throughput analysis technologies.
Atrandi Biosciences has raised €24M across 1 funding round from 5 investors, most recently a Series A round in Feb 2025. Based in Vilnius, Lithuania; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-02-19 | Series A | €24M |
| GRIDS Capital,Lux Capital,Metaplanet,Practica Capital,Vsquared Ventures |
| View deal → |
